

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 088362/0104

In re patent application of
MOSSAKOWSKA et al.

Serial No. 09/142,043

Filed: December 15, 1998

For: FRAGMENTS OF CR1 AND THEIR USE

MAR 12 1999

GROUP 1800

TRANSMITTAL

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Transmitted herewith is an Amendment in the above-captioned application.
The fee has been calculated as shown below. (Small entity fees indicated
in parentheses.)

CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee
Total Claims	29	-	36	0	18.00	
(Small Entity)					(9.00)	
Independent claims	8	-	3	5	78.00	195.00
(Small Entity)					(39.00)	
Multiple Dependent	0	-	0	0	260.00	
(Small Entity)					(130.00)	
Extension of Time	One Month		Two Months	Three Months	Four Months	Five Months
Fee	\$110		\$380	\$870	\$1360	\$1850
(Small Entity)	(\$55)		(\$190)	(\$435)	(\$680)	(\$925)
Total						\$195.00

A check in the amount of the above Total Fee is attached. This amount is
believed to be correct; however, the Commissioner is hereby authorized to
charge any deficiency or credit any overpayment to Deposit Account No. 19-
0741.

Respectfully submitted,


John P. Isacson
Reg. No. 33,715

Date: March 3, 1999

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007
(202) 672-5300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Attorney Docket No. 88362/104

In re patent application of
MOSSAKOWSKA et al.

Serial No. 09/142,043

Filed: December 1, 1998

For: FRAGMENTS OF CR1 AND THEIR USE

MAR 12 1999

GROUP 1800

PRELIMINARY AMENDMENT B

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-captioned patent application, kindly amend the application as follows:

IN THE CLAIMS

Please cancel claim 1-36 without prejudice or disclaimer.
Please add the claims set forth below.

37. An SCR3-derived polypeptide having 6 to 23 amino acid residues and comprising at least a portion of Sequence (I):

CNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSG (I), wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

- (a) GGRKVF and
(b) FELVGEPSIY.

38. The SCR3-derived polypeptide according to claim 37, further comprising a cysteine residue at the carboxyl terminus and the amino terminus of the polypeptide, thereby providing a capability to form a cyclic polypeptide via formation of a disulfide bond.

39. The SCR3-derived polypeptide according to claim 37, further comprising a chemically reactive amino acid residue at